Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Kayali, F. [1 ]
Janjua, M. A. [1 ]
Laber, D. A. [1 ]
Miller, D. M. [1 ]
Day, J. M. [1 ]
Kloecker, G. H. [1 ]
机构：
[1] Univ Louisville, Louisville, KY 40292 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19077
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [32] Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study
    Rossi, D
    Graziano, F
    Ugolini, M
    Dennetta, D
    Alessandroni, P
    Catalano, V
    Giordani, P
    Fedeli, SL
    Fedeli, A
    Catalano, G
    TUMORI JOURNAL, 2004, 90 (01): : 50 - 53
  • [33] A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC).
    Kouroussis, C
    Syrigos, K
    Potamianou, A
    Ziras, N
    Ziotopoulos, P
    Stergiou, J
    Ginopoulos, P
    Tselepatiotis, E
    Biozionelou, V
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 681S - 681S
  • [34] Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Ceresoli, GL
    Gregorc, V
    Cordio, S
    Bencardino, KB
    Schipani, S
    Cozzarini, C
    Bordonaro, R
    Villa, E
    LUNG CANCER, 2004, 44 (02) : 231 - 239
  • [35] Phase II trial of concurrent erlotinib in locally advanced non-small cell lung cancer (LA-NSCLC)
    Hansen, O.
    Knap, M.
    Khalil, A.
    Nyhus, C.
    Brink, C.
    Hoffmann, L.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S663 - S663
  • [36] Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan
    Hsia, T.
    Chang, G.
    Chen, Y.
    Lin, M.
    Su, W.
    Tsai, C.
    Tsai, C.
    Yang, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 375 - 375
  • [37] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [38] A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
    Sequist, L. V.
    Harb, W. A.
    Modiano, M.
    Jackman, D. M.
    Wong, K.
    Engelman, J. A.
    Nering, R.
    Onsum, M.
    Moyo, V. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients
    Schmittel, Alexander
    Knoedler, Maren
    Hortig, Patricia
    Schulze, Karsten
    Thiel, Eckhard
    Keilholz, Ulrich
    LUNG CANCER, 2007, 55 (01) : 109 - 113
  • [40] Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial
    Nelli, F
    Naso, G
    Ceratti, ADP
    Saltarelli, R
    D'Auria, G
    Lugini, A
    Ferraldeschi, R
    Picone, V
    Moscetti, L
    Cortesi, E
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (04) : 392 - 399
12345